A statement released earlier today by Jefferies International about Hikma Pharmaceuticals PLC (LON:HIK) maintains the target price at 2,990.00GBX
- Updated: September 18, 2016
Having a price of 0.00GBX, Hikma Pharmaceuticals PLC (LON:HIK) traded 0.80% lower on the day. The last stock price close is down 4.75% from the 200-day average, compared with the S&P 500 which has fallen -0.01% over the same time. HIK has been tracking to a 50-day moving average of 2,273.76GBX and 200-day moving average of 2,221.42GBX. Volume of trade was was down over the average, with 508,620 shares of HIK changing hands under the typical 581,547 shares.
Jefferies International held the target price of Hikma Pharmaceuticals PLC (LON:HIK) at 2,990GBX, indicating a possible upside of 0.00%,
Previously on 7/26/2016, Jefferies released a statement for Hikma Pharmaceuticals PLC(LON:HIK) bumped the target price from 2,800.00GBX to 2,990.00GBX that suggested an upside of 0.13%.
A total of 9 brokerages have released a report on HIK. Four analysts rate the stock a strong buy, six analysts rate the company a buy, 0 analysts rate the company a hold, 0 rate the company to underperform, and lastly 0 firmsrate the company as sell with a 12-month target stock price of 32.71GBX
With a market capitalization of 0.0 GBX, Hikma Pharmaceuticals PLC has a P/E of 26 with a 52 week low of 1,575.00GBX and a one-year high of 2,703.00GBX.
Brief Synopsis On Hikma Pharmaceuticals PLC (LON:HIK)
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company’s segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1, 120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business’ products include Argatroban, Fentanyl, Glycopyrrolate, and Nicardipine and Phenylephrine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.